Key Capital Management
EW icon

Key Capital Management’s Edwards Lifesciences EW Stock Holding History

Key Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.73K Hold
20
– – ﹤0.01% 617
2026
Q2 		$1.81K Hold
20
– – ﹤0.01% 598
2026
Q1 		$1.6K Hold
20
– – ﹤0.01% 566
2025
Q4 		$1.7K Buy
+20
New +$1.64K ﹤0.01% 401

Other funds holding EW

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mirova US
Mirova US Boston, Massachusetts $9.15B AUM 21.91% 1-Year Est. Return

Key Capital Management's EW Position: Q3 2026 in Review

Key Capital Management held its Edwards Lifesciences (EW) position steady in Q3 2026 at 20 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #617.

Key Capital Management first reported a position in EW in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.81K in Q2 2026. 851 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Key Capital Management held 20 shares of Edwards Lifesciences worth $1.73K as of Q3 2026.
  • Key Capital Management left its Edwards Lifesciences share count unchanged in Q3 2026.
  • Edwards Lifesciences made up ﹤0.01% of Key Capital Management's portfolio in Q3 2026, its #617 holding.
  • Key Capital Management first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 4 quarters since.
  • Key Capital Management's Edwards Lifesciences position peaked at $1.81K in Q2 2026.
  • 851 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Key Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.